Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Herz
Erschienen in: Herz 2/2011

01.03.2011 | Main topic/CME

Diabetic cardiomyopathy—fact or fiction?

Erschienen in: Herz | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Epidemiologic as well as clinical studies confirm the close link between diabetes mellitus and heart failure. Diabetic cardiomyopathy (DCM) is still a poorly understood “entity”, however, with several contributing pathogenetic factors which lead in different stages of diabetes to characteristic clinical phenotypes. Hyperglycemia with a shift from glucose metabolism to increased beta-oxidation and consecutive free fatty acid damage (lipotoxicity) to the myocardium, insulin resistance, renin-angiotensin-aldosterone system (RAAS) activation, altered calcium homeostasis and structural changes from the natural collagen network to a stiffer matrix due to advanced glycation endproduct (AGE) formation, hypertrophy and fibrosis contribute to the respective clinical phenotypes of DCM.
We propose the following classification of cardiomyopathy in diabetic patients:
a)
Diastolic heart failure with normal ejection fraction (HFNEF) in diabetic patients often associated with hypertrophy without relevant hypertension. Relevant coronary artery disease (CAD), valvular disease and uncontrolled hypertension are not present. This is referred to as stage 1 DCM.
 
b)
Systolic and diastolic heart failure with dilatation and reduced ejection (HFREF) in diabetic patients excluding relevant CAD, valvular disease and uncontrolled hypertension as stage 2 DCM.
 
c)
Systolic and/or diastolic heart failure in diabetic patients with small vessel disease (microvascular disease) and/or microbial infection and/or inflammation and/or hypertension but without CAD as stage 3 DCM.
 
d)
If heart failure may also be attributed to infarction or ischemia and remodeling in addition to stage 3 DCM the term should be heart failure in diabetes or stage 4 DCM.
 
These clinical phenotypes of diabetic cardiomyopathy can be separated by biomarkers, non-invasive (echocardiography, cardiac magnetic resonance imaging) and invasive imaging methods (levocardiography, coronary angiography) and further analysed by endomyocardial biopsy for concomitant viral infection. The role of specific diabetic drivers to the clinical phenotypes, to macro- and microangiopathy as well as accompanying risk factors or confounders, e.g. hypertension, autoimmune factors or inflammation with or without viral persistence, need to be identified in each individual patient separately. Thus hyperglycemia, hyperinsulinemia and insulin resistance as well as lipotoxicity by free fatty acids (FFAs) are the factors responsible for diabetic cardiomyopathy. In stage 1 and 2 DCM diabetic cardiomyopathy is clearly a fact. However, precise determination of to what degree the various underlying pathogenetic processes are responsible for the overall heart failure phenotype remains a fiction.
Literatur
1.
Abe T, Ohga Y, Tabayashi N et al (2002) Left ventricular diastolic dysfunction in type 2 diabetes mellitus model rats. Am J Physiol Heart Circ Physiol 282:H138–H148PubMed
2.
Achenbach S, Ropers D, Regenfus M et al (2001) Noninvasive coronary angiography by magnetic resonance imaging, electron-beam computed tomography, and multislice computed tomography. Am J Cardiol 88(2A):70E–73EPubMedCrossRef
3.
Alter P, Grimm W, Vollrath A et al (2006) Heart rate variability in patients with cardiac hypertrophy – relation to left ventricular mass and etiology. Am Heart J 151(4):829–836PubMedCrossRef
4.
Alter P, Rupp H, Rominger MB et al (2010) Late gadolinium enhancement is associated with increased left ventricular wall stress and mass in patients with non-ischemic cardiomyopathy. Eur Heart J 31(Supp 1):282
5.
Alter P, Rupp H, Rominger MB et al (2008) B-type natriuretic peptide and wall stress in dilated human heart. Mol Cell Biochem 314(1–2):179–191
6.
Alter P, Rupp H, Rominger MB et al (2008) A new methodological approach to assess cardiac work by pressure-volume and stress-length relations in patients with aortic valve stenosis and dilated cardiomyopathy. Pfluegers Arch 455(4):627–636
7.
Alter P, Rupp H, Rominger MB et al (2007) Relation of B-type natriuretic peptide to left ventricular wall stress as assessed by cardiac magnetic resonance imaging in patients with dilated cardiomyopathy. Can J Physiol Pharmacol 85(8):790–799PubMedCrossRef
8.
Alter P, Rupp H, Maisch B (2008) Assessment and relevance of ventricular wall stress in heart failure. Eur Heart J 29(18):2316PubMedCrossRef
9.
Alter P, Rupp H, Stoll F et al (2010) Left ventricular hypertrophy follows increased enddiastolic wall stress in patients with dilative heart failure. Clin Res Cardiol 99(Suppl 2). DOI: 10.1007/s00392-010-1200-0
10.
Aneja A, Tang WH, Bansilal S et al (2008) Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med 121(9):748–757PubMedCrossRef
11.
Argirova MD, Ortwerth BJ (2003) Activation of protein-bound copper ions during early glycation: study on two proteins. Arch Biochem Biophys 420:176–184PubMedCrossRef
12.
Aronow WS, Ahn C (1999) Incidence of heart failure in 2,737 older persons with and without diabetes mellitus. Chest 115:867–868PubMedCrossRef
13.
Bell DS (2003) Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 26(8):2433–2441PubMedCrossRef
14.
Bella JN, Devereux RB, Roman MJ et al (2001) Separate and joint effects of systemic hypertension and diabetes mellitus on left ventricular structure and function in American Indians (the Strong Heart Study). Am J Cardiol 87:1260–1265PubMedCrossRef
15.
Bertoni AG, Goff DC Jr, D’Agostino RB Jr et al (2006) Diabetic cardiomyopathy and subclinical cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care 29(3):588–594PubMedCrossRef
16.
Bertoni AG, Tsai A, Kasper EK, Brancati FL (2003) Diabetes and idiopathic cardiomyopathy: a nationwide case-control study. Diabetes Care 26:2791–2795PubMedCrossRef
17.
Boudina S, Abel ED (2006) Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes. Physiology 21:250–258PubMedCrossRef
18.
19.
Boudina S, Abel ED (2010) Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord 11:31–39PubMedCrossRef
20.
Boyer JK, Thanigaraj S, Schechtman KB et al (2004) Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol 93:870–875PubMedCrossRef
21.
Brilla CG (2000) Regression of myocardial fibrosis in hypertensive heart disease: diverse effects of various antihypertensive drugs. Cardiovasc Res 46:324–331PubMedCrossRef
22.
Brilla CG, Funck RC, Rupp H (2000) Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 102:1388–1393PubMed
23.
Cai L, Wang Y, Zhou G et al (2006) Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J Am Coll Cardiol 48:1688–1697PubMedCrossRef
24.
Charoenpanichkit C, Morgan TM, Hamilton CA et al (2010) Left ventricular hypertrophy influences cardiac prognosis in patients undergoing dobutamine cardiac stress testing. Circ Cardiovasc Imaging 3(4):392–397PubMedCrossRef
25.
Dhalla NS, Liu X, Panagia V, Takeda N (1998) Subcellular remodeling and heart dysfunction in chronic diabetes. Cardiovasc Res 40(2):239–247PubMedCrossRef
26.
Devereux RB, Roman MJ, Paranicas M et al (2000) Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 101(19):2271–2276PubMed
27.
Eckel J, Reinauer H (1990) Insulin action on glucose transport in isolated cardiac myocytes: signalling pathways and diabetes-induced alterations. Biochem Soc Trans 18:1125–1127PubMed
28.
Elliott P, Andersson B, Arbustini E et al (2008) Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. 29(2):270–276
29.
Fang ZY, Prins JB, Marwick TH (2004) Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 25(4):543–567PubMedCrossRef
30.
Fiordaliso F, Leri A, Cesselli D et al (2001) Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death. Diabetes 50:2363–2375PubMedCrossRef
31.
Gebker R, Mirelis JG, Jahnke C et al (2010) Influence of left ventricular hypertrophy and geometry on diagnostic accuracy of wall motion and perfusion magnetic resonance during dobutamine stress. Circ Cardiovasc Imaging 3(5):507–514PubMedCrossRef
32.
Ha JW, Lee HC, Kang ES et al (2007) Abnormal left ventricular longitudinal functional reserve in patients with diabetes mellitus: implication for detecting subclinical myocardial dysfunction using exercise tissue Doppler echocardiography. Heart 93(12):1571–1576PubMedCrossRef
33.
Havers J, Haude M, Erbel R, Spiller P (2008) Röntgendensitometische Messung der myokardialen Perfusionsreserve bei symptomatischen Patienten ohne angiographisch detektierbare Koronarstenosen. Herz 33:223–232PubMedCrossRef
34.
Herrero P, Peterson LR, McGill JB et al (2006) Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J Am Coll Cardiol 47:598–604PubMedCrossRef
35.
Hunt SA, American College of Cardiology, American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation, Management of Heart Failure) (2005) ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). JACC 46(6):e1–e82PubMed
36.
Iltis I, Kober F, Desrois M et al (2005) Defective myocardial blood flow and altered function of the left ventricle in type 2 diabetic rats: a noninvasive in vivo study using perfusion and cine magnetic resonance imaging. Invest Radiol 40(1):19–26PubMed
37.
Iribarren C, Karter AJ, Go AS et al (2001) Glycemic control and heart failure among adult patients with diabetes. Circulation 103:2668–2673PubMed
38.
Islam KN, Takahashi M, Higashiyama S et al (1995) Fragmentation of ceruloplasmin following nonenzymatic glycation reaction. J Biochem 118:1054–1060PubMed
39.
Jahnke C, Nagel E, Gebker R et al (2007) Prognostic value of cardiac magnetic resonance stress tests: adenosine stress perfusion and dobutamine stress wall motion imaging. Circulation 115(13):1769–1776PubMedCrossRef
40.
Kannel WB, McGee DL (1979) Diabetes and cardiovascular disease: the Framingham study. JAMA 241:2035–2038PubMedCrossRef
41.
Khavandi K, Khavandi A, Asghar O et al (2009) Diabetic cardiomyopathy-a distinct disease? Best Pract Res Clin Endocrinol Metab 23(3):347–360PubMedCrossRef
42.
Liang Q, Carlson EC, Donthi RV et al (2002) Overexpression of metallothionein reduces diabetic cardiomyopathy. Diabetes 51:174–181PubMedCrossRef
43.
Liedtke AJ, DeMaison L, Eggleston AM et al (1988) Changes in substrate metabolism and effects of excess fatty acids in reperfused myocardium. Circ Res 62:535–542PubMed
44.
Liu GX, Hanley PJ, Ray J, Daut J (2001) Long-chain acylcoenzyme A esters and fatty acids directly link metabolism to K (ATP) channels in the heart. Circ Res 88(9):918–924PubMedCrossRef
45.
46.
Ma H, Li AY, Xu P et al (2009) Advanced glycation endproduct (AGE) accumulation and AGE receptor (RAGE) upregulation contribute to the onset of diabetic cardiomyopathy. J Cell Mol Med 13(8B):1751–1764PubMedCrossRef
47.
Maisch B (2006) Obesity, diabetes mellitus and metabolic syndrome: the implications for heart and the vascular system. Herz 31(3):185–188PubMedCrossRef
48.
Maisch B, Hufnagel G, Kölsch S et al (2004) Treatment of inflammatory dilated cardiomyopathy and myocarditis with immunosuppression and i.v. immunoglobulins. Herz 29:624–636PubMedCrossRef
49.
Maisch B, Pankuweit S, Karatolios K, Ristić AD (2006) Invasive techniques – from diagnosis to treatment. Rheumatology (Oxford) 45(Suppl 4):iv32–iv38
50.
Maisch B, Richter A, Koelsch S et al (2006) Management of patients with suspected (peri-)myocarditis and inflammatory dilated cardiomyopathy. Herz 31(9):881–890PubMedCrossRef
51.
Maisch B, Rupp H (2006) Myocardial fibrosis: a cardiopathophysiologic Janus head. Herz 31(3):260–268PubMedCrossRef
52.
Maisch B, Seferovic PM, Ristic AD et al (2004) The Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology. Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European Society of Cardiology Eur Heart J 25(7):587–610
53.
Maksimović R, Dill T, Seferović PM et al (2006) Magnetic resonance imaging in pericardial diseases. Indications and diagnostic value. Herz 31(7):708–714PubMedCrossRef
54.
Malhotra A, Sanghi V (1997) Regulation of contractile proteins in diabetic heart. Cardiovasc Res 34:34–40PubMedCrossRef
55.
Matsushima S, Kinugawa S, Ide T et al (2006) Overexpression of glutathione peroxidase attenuates myocardial remodeling and preserves diastolic function in diabetic heart. Am J Physiol Heart Circ Physiol 291:H2237–H2245PubMedCrossRef
56.
Maya L, Villarreal FJ (2010) Diagnostic approaches for diabetic cardiomyopathy and myocardial fibrosis. J Mol Cell Cardiol 48:524–529PubMedCrossRef
57.
McGavock JM, Lingvay I, Zib I et al (2007) Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation 116:1170–1175PubMedCrossRef
58.
Murray AG, Anderson RE, Watson GC et al (2004) Uncoupling proteins in human heart. Lancet 364:1786–1788PubMedCrossRef
59.
Nagel E, Lorenz C, Baer F et al (2001) Stress cardiovascular magnetic resonance: consensus panel report. J Cardiovasc Magn Reson 3(3):267–281PubMedCrossRef
60.
Neubauer S, Krahe T, Schindler R et al (1992) 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation 86(6):1810–1818PubMed
61.
Neubauer S, Horn M, Cramer M et al (1997) Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 96(7):2190–2196PubMed
62.
63.
Ng ACT, Delgado V, Bertini M et al (2009) Findings from left ventricular strain and strain rate imaging in asymptomatic patients with type 2 diabetes mellitus. Am J Cardiol 104:1398–1401PubMedCrossRef
64.
Nichols GA, Hillier TA, Erbey JR, Brown JB (2001) Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 24:1614–1619PubMedCrossRef
65.
Palmieri V, Capaldo B, Russo C et al (2008) Uncomplicated type 1 diabetes and preclinical left ventricular myocardial dysfunction: insights from echocardiography and exercise cardiac performance evaluation. Diabetes Res Clin Pract 79(2):262–268PubMedCrossRef
66.
Pankuweit S, Funck R, Grimm W, Maisch B (2006) Diagnosis and treatment of inflammatory heart diseases: role of endomyocardial biopsy. Herz 31(4):361–365PubMedCrossRef
67.
Pankuweit S, Ruppert V, Maisch B (2004) Inflammation in dilated cardiomyopathy. Herz 29(8):788–793PubMedCrossRef
68.
Paulus WJ, Tschöpe C, Sanderson JE et al (2007) How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28(20):2539–2550PubMedCrossRef
69.
Peterson LR, Herrero P, Schechtman KB et al (2004) Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 109:2191–2196PubMedCrossRef
70.
Pogatsa G (2001) Metabolic energy metabolism in diabetes: therapeutic implications. Coron Artery Dis 12(Suppl 1):S29–S33PubMed
71.
Portig I, Maisch B (2004) Noninvasive methods in the diagnosis of macro- and microangiopathy of peripherial and carotid arteries. Herz 29(1):17–25PubMedCrossRef
72.
Regan TJ, Lyons MM, Ahmed SS et al (1977) Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 60(4):884–899PubMedCrossRef
73.
Richardson P, McKenna W, Bristow M et al (1996) Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 93(5):841–842PubMed
74.
Rijzewijk LJ, Meer RW van der, Lamb HJ et al (2009) Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol 54:1524–1532PubMedCrossRef
75.
Rodrigues B, Camm MC, Mcneill GH (1998) Metabolic disturbances in diabetic cardiomyopathy. Mol Cell Biochem 180:53–57PubMedCrossRef
76.
Rubler S, Dlugash J, Yuceoglu YZ et al (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30(6):595–602PubMedCrossRef
77.
Ryden L, Standl E, Bartnik M et al (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28(1):88–136PubMedCrossRef
78.
79.
Scognamiglio R, Avogaro A, Casara D et al (1998) Myocardial dysfunction and adrenergic cardiac innervations in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol 31(2):404–412PubMedCrossRef
80.
Shen X, Zheng S, Metreveli NS, Epstein PN (2006) Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes 55:798–805PubMedCrossRef
81.
Shimazu M, Umeda K, Sugihara N et al (1993) Collagen remodelling in myocardia of diabetic patients. J Clin Path 46:32–36CrossRef
82.
Soufi M, Sattler AM, Herzum M et al (2006) Molecular basis of obesity and the risk for cardiovascular disease. Herz 31(3):200–206PubMedCrossRef
83.
Stratmann B, Gawlowski T, Tschoepe D (2010) Diabetic cardiomyopathy-to take a long story serious. Herz 35(3):161–168PubMedCrossRef
84.
Stratmann B, Stork I, Tschoepe D (2008) Diabetic cardiomyopathy-a type of coronary artery disease? Internist 49(4):436–440PubMedCrossRef
85.
Stratton IM, Adler AI, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412PubMedCrossRef
86.
Swan GW, Anker SD, Walton C et al (1997) Insulin resistance in chronic failure: relation to severity and etiology of heart failure. J Am Coll Cardiol 30:527–532PubMedCrossRef
87.
Taegtmeyer H (2004) Cardiac metabolism as a target for the treatment of heart failure. Circulation 110:894–896PubMedCrossRef
88.
Takeda N, Nakamura I, Hatanaka T et al (1988) Myocardial mechanical and myosin isoenzyme alterations in streptozotocin-diabetic rats. Jpn Heart J 29:455–463PubMed
89.
Tarquini R, Lazzeri C, Pala L et al (2010) The diabetic cardiomyopathy. Acta Diabetol. DOI: 10.1007/s00592-010-0180-x
90.
Von Bibra H, Sutton J St M (2010) Diastolic dysfunction in diabetes and the metabolic syndrome: promising potential for diagnosis and prognosis. Diabetologia 53:1033–1045CrossRef
91.
Wachter R, Lüers C, Leta S et al (2007) Impact of diabetes on left ventricular diastolic function in patients with arterial hypertension. Eur J Heart Fail 9:469–476PubMedCrossRef
92.
Westermann D, Walther T, Savvatis K et al (2009) Gene deletion of the kinin receptor B1 attenuates cardiac inflammation and fibrosis during the development of experimental diabetic cardiomyopathy. Diabetes 58(6):1373–1381PubMedCrossRef
93.
Yim MB, Yim HS, Lee C et al (2001) Protein glycation: creation of catalytic sites for free radical generation. Ann N Y Acad Sci 928:48–53PubMedCrossRef
94.
Yu X, Tesiram YA, Towner RA et al (2007) Early myocardial dysfunction in streptozotocin-induced diabetic mice: a study using in vivo magnetic resonance imaging (MRI). Cardiovasc Diabetol 6:6PubMedCrossRef
Metadaten
Titel
Diabetic cardiomyopathy—fact or fiction?
Publikationsdatum
01.03.2011
Erschienen in
Herz / Ausgabe 2/2011
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-011-3429-4

Weitere Artikel der Ausgabe 2/2011

Herz 2/2011 Zur Ausgabe

Schwerpunkt/CME

Herzinsuffizienz

Schwerpunkt/CME

Die Rolle der Kardio-MRT bei Diagnose und Prognosebeurteilung der Herzinsuffizienz

Main topic/CME

Pathophysiology, diagnosis, and treatment of infarction-related cardiogenic shock

Schwerpunkt/CME

Psychosomatik der Herzinsuffizienz

Hot Topics

ROCKET AF

Image of the month

Atrial lipomatous hypertrophy causing reduction in systemic venous return

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise